DBV Technologies S.A. (DBV.PA)
EUR 0.61
(1.17%)
EUR 0.61
(1.17%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -67.26 Million EUR | 30.15% |
| 2022 | -96.3 Million USD | 1.54% |
| 2021 | -97.8 Million USD | 38.7% |
| 2020 | -159.55 Million EUR | 7.26% |
| 2019 | -172.04 Million EUR | 9.44% |
| 2018 | -189.97 Million EUR | -7.22% |
| 2017 | -177.18 Million EUR | -47.1% |
| 2016 | -120.45 Million EUR | -146.62% |
| 2015 | -48.84 Million EUR | -67.27% |
| 2014 | -29.19 Million EUR | -9.52% |
| 2013 | -26.65 Million EUR | -54.92% |
| 2012 | -17.2 Million EUR | -83.36% |
| 2011 | -9.38 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -27.34 Million USD | -144.46% |
| 2024 Q2 | -33.11 Million USD | -21.1% |
| 2023 Q1 | -22.26 Million USD | 43.26% |
| 2023 FY | -67.26 Million EUR | 30.15% |
| 2023 Q4 | -11.18 Million USD | 33.02% |
| 2023 Q3 | -16.7 Million USD | 31.11% |
| 2023 Q2 | -24.24 Million USD | -8.87% |
| 2022 Q3 | -16.55 Million USD | 25.62% |
| 2022 Q4 | -39.24 Million USD | -137.05% |
| 2022 Q1 | -16.7 Million USD | -22.18% |
| 2022 Q2 | -22.25 Million USD | -33.22% |
| 2022 FY | -96.3 Million USD | 1.54% |
| 2021 Q1 | -29.44 Million USD | 25.42% |
| 2021 Q2 | -30.65 Million USD | -4.09% |
| 2021 Q3 | -24.03 Million USD | 21.6% |
| 2021 Q4 | -13.67 Million USD | 43.11% |
| 2021 FY | -97.8 Million USD | 38.7% |
| 2020 Q1 | -40.91 Million USD | 18.68% |
| 2020 Q3 | -30.95 Million USD | 35.78% |
| 2020 FY | -159.55 Million EUR | 7.26% |
| 2020 Q4 | -39.48 Million USD | -27.55% |
| 2020 Q2 | -48.2 Million USD | -17.82% |
| 2019 FY | -172.04 Million EUR | 9.44% |
| 2019 Q4 | -50.3 Million EUR | -62.34% |
| 2019 Q1 | -44.76 Million USD | 19.5% |
| 2019 Q2 | -45.37 Million USD | -1.38% |
| 2019 Q3 | -30.99 Million EUR | 31.7% |
| 2018 FY | -189.97 Million EUR | -7.22% |
| 2018 Q4 | -55.6 Million EUR | -8.93% |
| 2018 Q3 | -51.04 Million EUR | -21.3% |
| 2018 Q2 | -42.07 Million USD | 5.21% |
| 2018 Q1 | -44.39 Million USD | 1.53% |
| 2017 Q2 | -41.42 Million USD | -7.06% |
| 2017 Q3 | -44.41 Million USD | -7.2% |
| 2017 Q4 | -45.08 Million USD | -1.51% |
| 2017 FY | -177.18 Million EUR | -47.1% |
| 2017 Q1 | -38.69 Million USD | -12.97% |
| 2016 Q1 | -28.15 Million USD | -71.7% |
| 2016 FY | -120.45 Million EUR | -146.62% |
| 2016 Q4 | -34.25 Million USD | 6.3% |
| 2016 Q3 | -36.55 Million USD | -33.15% |
| 2016 Q2 | -27.45 Million USD | 2.49% |
| 2015 Q1 | -6.58 Million USD | 11.06% |
| 2015 FY | -48.84 Million EUR | -67.27% |
| 2015 Q4 | -16.39 Million USD | 2.68% |
| 2015 Q3 | -16.84 Million USD | -81.24% |
| 2015 Q2 | -9.29 Million USD | -41.13% |
| 2014 Q4 | -7.4 Million USD | 4.09% |
| 2014 FY | -29.19 Million EUR | -9.52% |
| 2014 Q1 | -7.17 Million USD | 8.52% |
| 2014 Q2 | -8.98 Million USD | -25.14% |
| 2014 Q3 | -7.72 Million USD | 14.05% |
| 2013 Q2 | -5.13 Million USD | -1.46% |
| 2013 Q3 | -7.71 Million USD | -50.1% |
| 2013 Q4 | -7.84 Million USD | -1.74% |
| 2013 FY | -26.65 Million EUR | -54.92% |
| 2013 Q1 | -5.06 Million USD | -2.74% |
| 2012 Q3 | -4.8 Million USD | 0.0% |
| 2012 FY | -17.2 Million EUR | -83.36% |
| 2012 Q4 | -4.93 Million USD | -2.66% |
| 2011 FY | -9.38 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -1812.149% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 54.468% |
| Adocia SA | -21.16 Million EUR | -217.878% |
| Aelis Farma SA | -5.07 Million EUR | -1224.722% |
| Biophytis S.A. | -17.02 Million EUR | -295.098% |
| Advicenne S.A. | -7.03 Million EUR | -856.754% |
| genOway Société anonyme | 1.56 Million EUR | 4391.304% |
| IntegraGen SA | -171.39 Thousand EUR | -39147.254% |
| Medesis Pharma S.A. | -3.95 Million EUR | -1598.941% |
| Neovacs S.A. | -8.74 Million EUR | -669.369% |
| NFL Biosciences SA | -3.74 Million EUR | -1696.017% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 85069.371% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -2021.429% |
| Sensorion SA | -22.06 Million EUR | -204.891% |
| Theranexus Société Anonyme | -6.82 Million EUR | -885.206% |
| TME Pharma N.V. | -6.73 Million EUR | -898.655% |
| Valbiotis SA | -7.36 Million EUR | -812.994% |
| TheraVet SA | -1.57 Million EUR | -4182.747% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | -230.66% |
| argenx SE | -272.91 Million EUR | 75.352% |
| BioSenic S.A. | -28.77 Million EUR | -133.753% |
| Celyad Oncology SA | -8.44 Million EUR | -696.276% |
| Galapagos NV | 211.69 Million EUR | 131.776% |
| Genfit S.A. | -28.89 Million EUR | -132.814% |
| GeNeuro SA | -14.75 Million EUR | -355.847% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | -337.382% |
| Innate Pharma S.A. | -7.57 Million EUR | -788.631% |
| Inventiva S.A. | -110.42 Million EUR | 39.082% |
| MaaT Pharma SA | -19.71 Million EUR | -241.175% |
| MedinCell S.A. | -25.03 Million EUR | -168.669% |
| Nanobiotix S.A. | -39.7 Million EUR | -69.444% |
| Onward Medical N.V. | -36.18 Million EUR | -85.925% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -1906.279% |
| OSE Immunotherapeutics SA | -23 Million EUR | -192.438% |
| Oxurion NV | -18.96 Million EUR | -254.628% |
| Pharming Group N.V. | -9.75 Million EUR | -589.477% |
| Poxel S.A. | -35.09 Million EUR | -91.705% |
| GenSight Biologics S.A. | -26.22 Million EUR | -156.558% |
| Transgene SA | -22.32 Million EUR | -201.278% |
| Financière de Tubize SA | 88.15 Million EUR | 176.311% |
| UCB SA | 343 Million EUR | 119.612% |
| Valneva SE | -101.42 Million EUR | 33.678% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | -137.349% |